Federated Hermes, Inc. Ngm Biopharmaceuticals Inc Transaction History

Federated Hermes, Inc.

13 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Jan 31, 2024	SELL	$0.6 - $1.31 $144,124 - $314,672	-240,208 Reduced 41.02%	345,381 $297,000
Q3 2023 Nov 13, 2023	BUY	$1.05 - $3.37 $109 - $350	104 Added 0.02%	585,589 $626,000
Q2 2023 Aug 14, 2023	BUY	$2.44 - $4.53 $1.01 Million - $1.87 Million	412,097 Added 237.67%	585,485 $1.52 Million
Q1 2023 May 08, 2023	BUY	$3.72 - $5.4 $645,003 - $936,295	173,388 New	173,388 $707,000
Q1 2022 May 13, 2022	SELL	$13.81 - $18.6 $13 - $18	-1 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$17.26 - $22.02 $114,382 - $145,926	-6,627 Reduced 99.98%	1 $1,000
Q3 2021 Nov 15, 2021	SELL	$20.15 - $26.19 $1,007 - $1,309	-50 Reduced 0.75%	6,628 $139,000
Q2 2021 Aug 16, 2021	BUY	$15.06 - $30.03 $100,570 - $200,540	6,678 New	6,678 $132,000
Q4 2020 Feb 12, 2021	SELL	$16.21 - $31.44 $39,309 - $76,242	-2,425 Closed	0 $0
Q3 2020 Nov 12, 2020	SELL	$15.59 - $19.97 $3,991 - $5,112	-256 Reduced 9.55%	2,425 $39,000
Q2 2020 Aug 13, 2020	SELL	$11.97 - $23.47 $7,481 - $14,668	-625 Reduced 18.91%	2,681 $53,000
Q1 2020 May 13, 2020	SELL	$10.0 - $19.51 $4,810 - $9,384	-481 Reduced 12.7%	3,306 $41,000
Q4 2019 Feb 14, 2020	BUY	$9.97 - $20.28 $37,756 - $76,800	3,787 New	3,787 $70,000

2.6M

300

Ticker NGM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 80,365,904
Description
NGM Biopharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat liver and metabolic diseases, retinal diseases, and cancer. The company's product candidates include Aldafermin, an engineered analog of human hormone fibroblast growth factor 19, which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Federated Hermes, Inc., based on Form 13F filings with the SEC.

Stay updated on Federated Hermes, Inc. with notifications on news.